Pilaralisib
As of the edition of 20 October 2026, Pilaralisib is a small molecule: went quiet in 2018; acts on PIK3CA, PIK3CB and PIK3CD and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2018
- Kind
- Small molecule
- Registered trials
- 13, 1 stopped early
- Disease areas
- Cancer; Lungs and airways; Skin and connective tissue; Pregnancy and women's health; Urinary and reproductive; Blood and lymph
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
8 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product8 company-target rows are on route A because of Pilaralisib.
See the 8 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| PIK3CD | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | O00329 |
| PIK3CA | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | P42336 |
| PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | P42338 |
| PIK3CG | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | P48736 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 9 | 8 | 0 | 1 |
| Phase 2 | 4 | 4 | 0 | 0 |
| All trials | 13 |